Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05731284 · ClinicalTrials.gov registry record · NA
Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surgery
A NA study of Pelvic Organ Prolapse, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05731284: Active NA study of Pelvic Organ Prolapse, sponsored by University of Alabama at Birmingham.
NCT05731284 is a NA study of Pelvic Organ Prolapse that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 60 participants, below the 144-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05731284, a NA study of Pelvic Organ Prolapse, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the surgical outcomes of injecting platelet-rich plasma (PRP) into the vaginal tissue as an adjunct therapy at the time of prolapse surgery
Primary Outcome
Anterior wall descensus measured by the POP-Q System, Ba point
Conditions Studied
Interventions
- PROCEDURE Placebo
- PROCEDURE Platelet rich plasma (PRP) Injection
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What the registry record for NCT05731284 still lists
NCT05731284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 144-participant average among 40 other Pelvic Organ Prolapse trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Pelvic Organ Prolapse appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05731284 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05731284 about?
NCT05731284 is a clinical study titled "Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surgery". The purpose of the study is to evaluate the surgical outcomes of injecting platelet-rich plasma (PRP) into the vaginal tissue as an adjunct therapy at the time of prolapse surgery
What is the current status of trial NCT05731284?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2023-07-01. Estimated completion is 2028-12-31.
What conditions does trial NCT05731284 study?
This clinical trial studies the following conditions: Pelvic Organ Prolapse.
What interventions are being tested in trial NCT05731284?
The interventions under investigation include: Placebo (PROCEDURE), Platelet rich plasma (PRP) Injection (PROCEDURE).
Who is sponsoring clinical trial NCT05731284?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05731284 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pelvic Organ Prolapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05731284's enrollment target sits among peer trials
60 34th of 40 higher than 7 of 40 other Pelvic Organ Prolapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pelvic Organ Prolapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SORE Study: Sitz Baths After Urogynecologic Reconstruction
RECRUITING · NA
-
POMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment
RECRUITING · NA
-
Sequence of Midurethral Sling Placement During Robotic Sacrocolpopexy
RECRUITING · NA
-
The AccelERate Trial
RECRUITING · NA
-
Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery
ACTIVE NOT RECRUITING · NA
-
Clinical Investigation of the da Vinci Surgical System
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI